SPX3,585.62-54.85 -1.51%
DIA287.30-4.91 -1.68%
IXIC10,575.62-161.89 -1.51%

BRIEF-Transcenta Says Received IND Clearance From FDA For Its First-In-Class Gremlin1 Targeting Antibody TST003 For The Treatment Of Solid Tumors

BRIEF-Transcenta Says Received IND Clearance From FDA For Its First-In-Class Gremlin1 Targeting Antibody TST003 For The Treatment Of Solid Tumors

Reuters · 09/14/2022 02:17
BRIEF-Transcenta Says Received IND Clearance From FDA For Its First-In-Class Gremlin1 Targeting Antibody TST003 For The Treatment Of Solid Tumors

- Transcenta Holding Limited 6628.HK:

  • TRANSCENTA RECEIVED IND CLEARANCE FROM FDA FOR ITS FIRST-IN-CLASS GREMLIN1 TARGETING ANTIBODY TST003 FOR THE TREATMENT OF SOLID TUMORS

Source text for Eikon: ID:

Further company coverage: 6628.HK


((Reuters.Briefs@thomsonreuters.com;))